• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

晚期乳腺癌:资源利用及成本影响

Advanced breast cancer: use of resources and cost implications.

作者信息

Richards M A, Braysher S, Gregory W M, Rubens R D

机构信息

ICRF Clinical Oncology Unit, Guy's Hospital, London, UK.

出版信息

Br J Cancer. 1993 Apr;67(4):856-60. doi: 10.1038/bjc.1993.157.

DOI:10.1038/bjc.1993.157
PMID:8471446
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1968338/
Abstract

Little information is currently available on the use of hospital resources and the resulting costs of treating any advanced cancer. Such data may be useful for planning purposes and for calculating the cost effectiveness of measures designed to reduce the incidence of advanced disease (such as the National Breast Screening Programme). A retrospective analysis of the medical records of 50 patients with advanced breast cancer who attended the Guy's Hospital Oncology Unit and who died between October 1988 and December 1990 has therefore been undertaken. For each patient, the duration of in-patient stays and principal indications for admissions were recorded, together with the number of out-patient attendances. Details of endocrine treatment, chemotherapy and radiotherapy were abstracted as were all radiological and laboratory investigations. Costs for each of these activities were calculated. The median duration of advanced disease was 17 months (mean 27 months; range 7 days-12 years). The mean cost of treatment per patients was calculated to be 7,620 pounds (range 317 pounds-27,860 pounds). Mean duration of in-patient stay was 32 days (0-133) and this accounted for 56% of total costs. The large majority (> 80%) of the time spent as an in-patient was for the care of serious illness rather than for specific antitumour treatment. Cytotoxic drugs accounted for 9% of the total cost, compared with 8% for radiotherapy and 13% for laboratory and radiological investigations.

摘要

目前关于医院资源的使用以及治疗任何晚期癌症所产生的费用的信息很少。这些数据可能对规划目的以及计算旨在降低晚期疾病发病率的措施(如国家乳腺癌筛查计划)的成本效益有用。因此,对1988年10月至1990年12月期间在盖伊医院肿瘤科就诊并死亡的50例晚期乳腺癌患者的病历进行了回顾性分析。记录了每位患者的住院时间和主要入院指征,以及门诊就诊次数。提取了内分泌治疗、化疗和放疗的详细信息,以及所有的放射学和实验室检查。计算了这些活动中每一项的费用。晚期疾病的中位持续时间为17个月(平均27个月;范围7天至12年)。每位患者的平均治疗费用计算为7620英镑(范围317英镑至27860英镑)。平均住院时间为32天(0至133天),这占总费用的56%。住院时间的绝大多数(>80%)用于重病护理而非特定的抗肿瘤治疗。细胞毒性药物占总费用的9%,放疗占8%,实验室和放射学检查占13%。

相似文献

1
Advanced breast cancer: use of resources and cost implications.晚期乳腺癌:资源利用及成本影响
Br J Cancer. 1993 Apr;67(4):856-60. doi: 10.1038/bjc.1993.157.
2
Introduction of a breast cancer care programme including ultra short hospital stay in 4 early adopter centres: framework for an implementation study.在4个早期采用中心引入包括超短住院时间的乳腺癌护理计划:一项实施研究的框架
BMC Cancer. 2007 Jul 2;7:117. doi: 10.1186/1471-2407-7-117.
3
Small bowel obstruction due to postoperative adhesions: treatment patterns and associated costs in 110 hospital admissions.术后粘连所致小肠梗阻:110例住院病例的治疗模式及相关费用
Ann R Coll Surg Engl. 2001 Jan;83(1):40-6.
4
Breast cancer management: quality-of-life and cost considerations.乳腺癌管理:生活质量与成本考量
Pharmacoeconomics. 2003;21(6):383-96. doi: 10.2165/00019053-200321060-00003.
5
Resource implications of palliative chemotherapy for ovarian cancer.卵巢癌姑息化疗的资源影响
J Clin Oncol. 1997 Mar;15(3):1000-7. doi: 10.1200/JCO.1997.15.3.1000.
6
Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.原发性乳腺癌患者脑转移的流行病学与经济负担:来自美国索赔数据分析的结果
Breast Cancer Res Treat. 2008 Mar;108(2):297-305. doi: 10.1007/s10549-007-9601-0. Epub 2007 Jun 19.
7
Costs incurred by patients undergoing advanced colorectal cancer therapy. A comparison of raltitrexed and fluorouracil plus folinic acid.晚期结直肠癌患者接受治疗的费用。雷替曲塞与氟尿嘧啶加亚叶酸的比较。
Pharmacoeconomics. 2000 Apr;17(4):361-70. doi: 10.2165/00019053-200017040-00006.
8
Mammography screening: an incremental cost effectiveness analysis of two view versus one view procedures in London.乳房X线筛查:伦敦地区双视图与单视图检查程序的增量成本效益分析
J Epidemiol Community Health. 1995 Feb;49(1):70-8. doi: 10.1136/jech.49.1.70.
9
Cost-effectiveness of a short stay admission programme for breast cancer surgery.乳腺癌手术短期住院方案的成本效益。
Acta Oncol. 2010 Apr;49(3):338-46. doi: 10.3109/02841861003610192.
10
Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis.精神分裂症给英国社会带来的成本。一种基于发病率的疾病成本模型,用于诊断后的前5年。
Pharmacoeconomics. 1999 Jun;15(6):597-610. doi: 10.2165/00019053-199915060-00007.

引用本文的文献

1
JMJD family proteins in cancer and inflammation.JMJD 家族蛋白在癌症和炎症中的作用。
Signal Transduct Target Ther. 2022 Sep 1;7(1):304. doi: 10.1038/s41392-022-01145-1.
2
Cost-effectiveness of early detection of breast cancer in Catalonia (Spain).在加泰罗尼亚(西班牙)进行乳腺癌早期检测的成本效益分析。
BMC Cancer. 2011 May 23;11:192. doi: 10.1186/1471-2407-11-192.
3
Health care costs for the treatment of breast cancer recurrent events: estimates from a UK-based patient-level analysis.乳腺癌复发事件的治疗医疗费用:基于英国患者层面分析的估计
Br J Cancer. 2007 Aug 20;97(4):479-85. doi: 10.1038/sj.bjc.6603887. Epub 2007 Jul 24.
4
Correlation between bone scintigraphy and tumor markers in patients with breast carcinoma.乳腺癌患者骨闪烁显像与肿瘤标志物之间的相关性
Bosn J Basic Med Sci. 2006 Feb;6(1):75-7. doi: 10.17305/bjbms.2006.3216.
5
Role of bone scintigraphy and tumor marker-Ca 15-3 in detection of bone metastases in patients with breast cancer.骨闪烁扫描术和肿瘤标志物Ca 15-3在乳腺癌患者骨转移检测中的作用
Bosn J Basic Med Sci. 2005 Feb;5(1):23-6. doi: 10.17305/bjbms.2005.3331.
6
Cost of managing women presenting with stage IV breast cancer in the United Kingdom.英国IV期乳腺癌女性患者的治疗成本。
Br J Cancer. 2004 Jul 5;91(1):77-83. doi: 10.1038/sj.bjc.6601890.
7
Bone resorption predicts for skeletal complications in metastatic bone disease.
Br J Cancer. 2003 Dec 1;89(11):2031-7. doi: 10.1038/sj.bjc.6601437.
8
Clinical and economic issues in the treatment of advanced breast cancer with bisphosphonates.双膦酸盐治疗晚期乳腺癌的临床与经济问题
Drugs Aging. 2003;20(9):631-42. doi: 10.2165/00002512-200320090-00001.
9
Efficacy and economics of hormonal therapies for advanced breast cancer.晚期乳腺癌激素疗法的疗效与经济学分析
Drugs Aging. 2002;19(6):453-63. doi: 10.2165/00002512-200219060-00004.
10
Bisphosphonates in the treatment of metastatic breast cancer.双膦酸盐类药物在转移性乳腺癌治疗中的应用
J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):477-85. doi: 10.1023/a:1014795216669.

本文引用的文献

1
Palliative radiotherapy--counting the costs of changing practice.姑息性放疗——计算改变治疗方式的成本
Health Policy. 1991 Apr;17(3):243-56. doi: 10.1016/0168-8510(91)90127-j.
2
The cost of radiotherapy treatments on a linear accelerator.直线加速器放射治疗的费用。
Br J Radiol. 1984 Jan;57(673):106-7. doi: 10.1259/0007-1285-57-673-106.
3
The cost of radiotherapy treatments on a linear accelerator.直线加速器放射治疗的成本。
Br J Radiol. 1983 Mar;56(663):189-91. doi: 10.1259/0007-1285-56-663-189.
4
Counting the costs of cancer therapy.计算癌症治疗的成本。
Eur J Cancer Clin Oncol. 1982 Dec;18(12):1237-41. doi: 10.1016/0277-5379(82)90124-9.
5
Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis.
Cancer. 1981 Oct 15;48(8):1749-53. doi: 10.1002/1097-0142(19811015)48:8<1749::aid-cncr2820480810>3.0.co;2-x.
6
The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group.脑转移瘤的姑息治疗:放射治疗肿瘤学组前两项研究的最终结果。
Int J Radiat Oncol Biol Phys. 1980 Jan;6(1):1-9. doi: 10.1016/0360-3016(80)90195-9.
7
Management importance of common treatments: contribution of top 20 procedures to surgical workload and cost.常见治疗方法的管理重要性:前20种手术操作对手术工作量和成本的贡献。
BMJ. 1991 Apr 13;302(6781):882-4. doi: 10.1136/bmj.302.6781.882.
8
Estimating the treatment costs of breast and lung cancer.估算乳腺癌和肺癌的治疗费用。
Med Care. 1991 Jan;29(1):40-9. doi: 10.1097/00005650-199101000-00004.
9
Acute myeloblastic leukaemia--a model for assessing value for money for new treatment programmes.急性髓细胞白血病——评估新治疗方案性价比的一个模型
BMJ. 1991 Feb 9;302(6772):323-6. doi: 10.1136/bmj.302.6772.323.
10
Auditing palliative cancer chemotherapy.姑息性癌症化疗审计
Eur J Cancer. 1990;26(10):1023-5. doi: 10.1016/0277-5379(90)90041-q.